Skip to main content

Lawrence Green, MD

Lawrence Green, MD
The psoriasis treatment landscape keeps changing for the better, with newer injectable and topical therapies available for patients with mild, moderate, and severe disease. Within the past 2 years alone, the FDA has approved some new indications for already existing therapies and new topical formulations.
Lawrence Green, MD
Lawrence Green, MD, shares his perspective on a recent article that showed step therapy and prior authorizations negatively impacted patient care and treatment adherence.  
Lawrence Green, MD
This article discusses the latest evidence on oral molecules for the treatment of psoriasis and psoriatic arthritis.
Lawrence Green, MD
In the current managed care environment, it is harder for dermatologists to place their patients on what they feel is the best choice medication for each patient.
Back to Top